Home » Topics » BioWorld Science

BioWorld Science
RSS

ArQule-Roche Bioscience collaborative agreement

Oct. 11, 1996

First launch for olanzapine

Oct. 11, 1996

Potential antipsychotic agents disclosed by Pharmacia & Upjohn

Oct. 11, 1996

Dopamine D3 ligands from Pharmacia & Upjohn

Oct. 11, 1996

New dopamine receptor ligands reported by Neurogen

Oct. 11, 1996

Suntory reports agents for CNS and cerebrovascular disorders

Oct. 11, 1996

Hypnotic agent in the Fujisawa pipeline

Oct. 11, 1996

Sonus and Abbott sign second licensing agreement for EchoGen

Oct. 11, 1996

Second approval for CEA-Scan

Oct. 11, 1996

Diatide begins phase II trial of imaging agent for locating infections

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...